Mechanism by which metformin reduces glucose production in type 2 diabetes - Test2 - elhamkhani - TriplyDB

Mechanism by which metformin reduces glucose production in type 2 diabetes

Mechanism by which metformin reduces glucose production in type 2 diabetes

http://www.wikidata.org/entity/Q22241286

about

sameAs

Role of AMP-activated protein kinase in mechanism of metformin action Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle Repurposing metformin: an old drug with new tricks in its binding pockets Metformin and body weight Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase Metformin for women who are obese during pregnancy for improving maternal and infant outcomes Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents The AMPK signalling pathway coordinates cell growth, autophagy and metabolism Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome Pancreatic regulation of glucose homeostasis Endoplasmic reticulum stress: a novel mechanism and therapeutic target for cardiovascular diseases Current understanding of metformin effect on the control of hyperglycemia in diabetes Measurements of Gluconeogenesis and Glycogenolysis: A Methodological Review AMP-activated protein kinase: a target for drugs both ancient and modern Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium Cellular and molecular mechanisms of metformin: an overview AMPK activation through mitochondrial regulation results in increased substrate oxidation and improved metabolic parameters in models of diabetes Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.(+)-Rutamarin as a Dual Inducer of Both GLUT4 Translocation and Expression Efficiently Ameliorates Glucose Homeostasis in Insulin-Resistant Mice Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review Better Living through Chemistry: Caloric Restriction (CR) and CR Mimetics Alter Genome Function to Promote Increased Health and Lifespan Cancer stem cell metabolism: a potential target for cancer therapy Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models Chicoric acid is an antioxidant molecule that stimulates AMP kinase pathway in L6 myotubes and extends lifespan in Caenorhabditis elegans Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose-dependent manner In Vitro Anti-Echinococcal and Metabolic Effects of Metformin Involve Activation of AMP-Activated Protein Kinase in Larval Stages of Echinococcus granulosus Genomic Characterization of Metformin Hepatic Response The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia A genome-wide siRNA screen to identify modulators of insulin sensitivity and gluconeogenesis The LKB1-AMPK pathway: metabolism and growth control in tumour suppression Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential

P2860

Q22241898-578AF82B-ECAF-4BE4-9C03-822F31C46F96 Q22241966-5C305C20-F77F-4F1D-BDCD-01FC93561C20 Q22250976-8EFC3729-212B-4524-98F3-ACB48E707AF2 Q22250988-5AE41662-9172-4C18-A11B-DB5C4918081F Q22251079-EB5FDE4F-ED69-487F-858B-B0771490B6F1 Q24202468-10F785B1-2B29-4CC3-BD0C-7A7A1E68EC1A Q24235718-8B6D967E-DC0F-4B74-BBEA-0643A235C516 Q24240522-A27D4E09-5989-48B8-AB6B-DC4B934598B0 Q24241119-BD1799B2-B888-410E-BACE-EEFA6884D00A Q24616273-2C8748E0-8760-4655-9090-2D377065A2DA Q24630971-A40B37E3-8E5E-449B-A771-219BD2A37B6E Q24803696-DEA43183-9A4C-405F-9355-B3C52347F722 Q26766485-E5DF323F-4425-4287-8345-5E77FBEDD62B Q26770193-C7554742-1154-4157-A74A-7EA88F408D19 Q26770236-69E25D47-EF90-40F3-B60F-B43E1B5B7711 Q26776006-BEC947E5-F6D3-4467-A56A-7694F26F7A09 Q26864424-74739DE7-4F9A-40C8-8B32-ACDA69496BB2 Q26991523-C5E9E1D7-C345-404F-8FBB-E3F359D27E90 Q26999344-B7D0761B-3C16-4A4F-B468-D41C7C0CFA01 Q27013561-BBDF2600-4B8C-42FF-A4A7-EA2DDAF55A54 Q27300811-209BA915-FED0-4409-86AF-E6436CE12E3E Q27301246-7B3C7577-59BB-48A3-9BA5-B3572C6AB60E Q27335063-DDBD7B8B-89BF-47CC-AB47-BD76CD84AAA4 Q27677636-3E472B64-5DAF-413C-83B8-59061B9CD01D Q28071386-B6623936-48F6-4C6D-BD68-BB7625EC9E35 Q28073173-6EE00AD2-D052-411A-AE28-8FD002E2762A Q28079045-2D726CE8-2D72-4DAF-88E6-BB37FCF969E8 Q28193039-CFCE96EE-569F-469F-AE6F-F15E6C5616A7 Q28486189-50C97791-7237-4135-9F6E-8114A6807ECA Q28508387-10A44F3A-81C8-4401-A7F6-5AA277E60F0A Q28534604-10D3D2E9-77CD-4D07-A042-610E295D68BF Q28535013-11322E3C-63CD-4293-8551-9A9CB466E64B Q28539904-3C32DDFA-5A01-4B96-AD90-C222F8A7E6D4 Q28547202-AC2EC6B1-5326-4683-B877-3DFAC889CC59 Q28554592-C3475A2F-1BA5-4AAB-A268-3E3FC6AB9580 Q28574993-DBD98C83-7968-4FE7-82F2-E148AD719EDC Q28581219-F82A4581-52E9-472B-8C39-A41B2419AB87 Q28730046-E41FFF79-7CC4-4008-B884-E811EBBEB018 Q29617506-FF1CF14C-0613-4A5D-8AD6-1A753F1B70E4 Q29994589-FF2EB23F-A2F8-4FB8-BAD5-45B274472330

P2860

Mechanism by which metformin reduces glucose production in type 2 diabetes

http://www.wikidata.org/entity/Q22241286

description

2000 nî lūn-bûn

@nan

2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Mechanism by which metformin reduces glucose production in type 2 diabetes

@ast

Mechanism by which metformin reduces glucose production in type 2 diabetes

@en

Mechanism by which metformin reduces glucose production in type 2 diabetes

@en-gb

Mechanism by which metformin reduces glucose production in type 2 diabetes

@nl

type

label

Mechanism by which metformin reduces glucose production in type 2 diabetes

@ast

Mechanism by which metformin reduces glucose production in type 2 diabetes

@en

Mechanism by which metformin reduces glucose production in type 2 diabetes

@en-gb

Mechanism by which metformin reduces glucose production in type 2 diabetes

@nl

prefLabel

Mechanism by which metformin reduces glucose production in type 2 diabetes

@ast

Mechanism by which metformin reduces glucose production in type 2 diabetes

@en

Mechanism by which metformin reduces glucose production in type 2 diabetes

@en-gb

Mechanism by which metformin reduces glucose production in type 2 diabetes

@nl

P1433

Q22241286-37AA4083-0790-4BFC-B43F-88D721B6845B

P1476

Q22241286-46BC8045-FB17-4EA7-BFC0-469D0232AE36

P2093

Q22241286-08353240-CDBF-40A8-8B84-752D2E216A2B

Q22241286-0B3179BE-0654-4FB7-BC97-7940ADD0FE10

Q22241286-406696FF-8FC8-4893-9BCA-3A014FB84FFE

Q22241286-5F9A3065-3FC2-40B3-96A2-6BF67DFE730C

Q22241286-61BC01F7-5135-49B6-9939-F9CCF9211BEC

Q22241286-9B2745C2-9180-4148-9C3D-034F69397B2F

Q22241286-9B73D3F1-2D13-4B26-90F3-DF4EBBA4972C

Q22241286-C1519F8A-C60D-4543-B38A-F603636AC65E

Q22241286-C71DFB8D-4689-41D4-A13D-53294FBE244E

Q22241286-EF6957C0-868A-47A8-9F12-E92093E6C512

P2860

Q22241286-01B0C917-E6B0-4FCA-87BC-8A5B47C5BF08

Q22241286-049560D0-2587-4D26-840D-84CB4FC842A9

Q22241286-18756C16-D627-454D-A10D-0B179AEEF1AB

Q22241286-33540BAA-E8FA-46F1-8DFA-2C04AC60E432

Q22241286-3E226387-DCC1-4D53-84CD-3B297D6302B6

Q22241286-3EEC83A8-F134-47AD-82FF-6C0C75741390

Q22241286-3FFF3DF1-5FA5-4DF5-8C75-3C77DC7E1694

Q22241286-428C2549-9C2D-436A-94AB-D0D41BD47ED1

Q22241286-469F8B58-6253-434B-BABC-96136481A5AA

Q22241286-4FE4DCE4-96ED-4280-9970-16925BD66E97

P304

Q22241286-D52290B7-C07D-4352-8655-1B5E8858C62C

P31

Q22241286-747F4E33-F638-41F0-96D0-F86FD1CEFB13

P3181

Q22241286-B340718F-164F-489F-89AF-732D06289D5A

P356

Q22241286-4BA1C1F9-498E-4371-8F86-981D2F09A7FB

P407

Q22241286-94D14937-B4FA-4A31-9CEF-BF100D89E261

P433

Q22241286-15623D4F-0DB5-4D21-8807-E252B3B70C7B

P478

Q22241286-55B20508-3831-472C-AD6F-9E4C5B313212

P577

Q22241286-97370C01-F96E-431D-BE48-7024BA236110

P5875

Q22241286-087263AB-6752-40D5-9A60-8A7F3A79C46A

P698

Q22241286-0AA8FEA9-4462-4233-B346-0C22DBDE40BF

P921

Q22241286-9C5A3DEF-1BBA-4B74-8902-BF68ADF5D7BB

Q22241286-E487C924-2FC0-44D3-A085-DC3AC85E79EA

Q22241286-F1089B20-694B-4F6A-893C-C9A2C588C940

Q22241286-f74db892-96aa-45ea-975e-5f5467377cf5

P932

Q22241286-F070CFD4-3344-4769-8A60-F3458979C6C5

P3181

P356

DIABETES.49.12.2063

P1433

P1476

Mechanism by which metformin reduces glucose production in type 2 diabetes

@en

P2093

B. R. Landau

http://www.w3.org/2001/XMLSchema#string

D. Laurent

http://www.w3.org/2001/XMLSchema#string

G. I. Shulman

http://www.w3.org/2001/XMLSchema#string

K. F. Petersen

http://www.w3.org/2001/XMLSchema#string

M. Krssak

http://www.w3.org/2001/XMLSchema#string

R. S. Hundal

http://www.w3.org/2001/XMLSchema#string

S. Dufour

http://www.w3.org/2001/XMLSchema#string

S. E. Inzucchi

http://www.w3.org/2001/XMLSchema#string

V. Chandramouli

http://www.w3.org/2001/XMLSchema#string

V. Lebon

http://www.w3.org/2001/XMLSchema#string

P2860

Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis.

Central role of the adipocyte in insulin resistance.

Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin.

Use of 2H2O for estimating rates of gluconeogenesis. Application to the fasted state.

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.

Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR.

Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study.

Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus.

Contributions of gluconeogenesis to glucose production in the fasted state.

P304

2063-2069

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1274001

http://www.w3.org/2001/XMLSchema#string

P356

10.2337/DIABETES.49.12.2063

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2000-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12210551

http://www.w3.org/2001/XMLSchema#string

P698

11118008

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2995498

http://www.w3.org/2001/XMLSchema#string